Zota Health Care Ltd
Pharmaceuticals & Biotechnology | Small Cap
Zota Health Care Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company maintains strong solvency due to a high equity ratio and no debt, which provides a stable financial foundation. However, liquidity is poor, indicating potential challenges in meeting short-term obligations. Efficiency is also low, with minimal turnover in fixed assets, inventory, and receivables, though the company benefits from high scores in days sales in inventory and receivable days. Growth metrics are weak, except for a high asset growth rate, suggesting significant investments in assets but struggling profitability. Financial ratios are average, with low adjusted EPS but reasonable cash EPS and dividend payouts. Profitability metrics are generally poor, reflecting low returns on capital, equity, and assets. While the asset growth is a positive sign, the company needs to improve its profitability and efficiency to ensure long-term financial health.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.80
- Financial Ratio4.40
- Profitability Ratio2.00
- Efficiency Ratio4.67
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourNeutral
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekNeutral
- 1 MonthBearish
Zota Health Care Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company maintains strong solvency due to a high equity ratio and no debt, which provides a stable financial foundation. However, liquidity is poor, indicating potential challenges in meeting short-term obligations. Efficiency is also low, with minimal turnover in fixed assets, inventory, and receivables, though the company benefits from high scores in days sales in inventory and receivable days. Growth metrics are weak, except for a high asset growth rate, suggesting significant investments in assets but struggling profitability. Financial ratios are average, with low adjusted EPS but reasonable cash EPS and dividend payouts. Profitability metrics are generally poor, reflecting low returns on capital, equity, and assets. While the asset growth is a positive sign, the company needs to improve its profitability and efficiency to ensure long-term financial health.
Overall Valuation Score
P/E RATIO (TTM)
162.23
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
-61.25
P/B RATIO
6.54
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
8.37
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
245.43
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1307.6 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth ratios show a mixed performance. While asset growth is strong, indicating significant investments, revenue, operating profit, EPS, and net income growth are low. This suggests that the company is investing in assets without generating corresponding revenue or profit increases. This assessment is based on a weighted average calculation, emphasizing recent performance.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 23.58 | 6.11 | 29.5 | 62.22 | 84.59 |
| Operating Profit Growth Rate | 1400 | -53.33 | 14.29 | -175 | -416.67 |
| Earnings Per Share (EPS) Growth | -4033.33 | -164.69 | 142.36 | 254.95 | 8.38 |
| Asset Growth Rate | 63.53 | 13.67 | 44.3 | 92.54 | 157.63 |
| Net Income Growth Rate | -166.67 | 133.33 | 307.14 | 29.82 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present strengths in Cash Earnings Per Share (EPS), Dividend Per Share (DPS), and Capital Expenditures (CapEx). Adjusted Earnings Per Share (Adjusted EPS) and Book Value Per Share are areas needing improvements. This assessment is based on a weighted average calculation, emphasizing recent performance.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 3.6 | -2.8 | -5.38 | -19.66 | -19.71 |
| Cash Earnings Per Share (Cash EPS) | 5.2 | 2.4 | 2.31 | -4.83 | 2.29 |
| Book Value Per Share | 35.6 | 32 | 34.62 | 77.24 | 198.29 |
| Dividend Per Share (DPS) | 1.49 | 1.01 | 1 | 0.98 | 1.07 |
| Capital Expenditures (CapEx) | 3 | 11 | 17 | 46 | 113 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are generally poor, with all metrics (Gross Profit Margin, ROCE, ROE, ROA, Operating Margin, and Net Margin) scoring low. This suggests that the company is struggling to generate profits from its operations and investments. This assessment is based on a weighted average calculation, emphasizing recent performance.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 8.4 | -3.6 | -6.67 | -16.78 | -11.69 |
| Return on Capital Employed (ROCE) | 15 | -2 | -7 | -17 | -8 |
| Return on Equity (ROE) | 10.11 | -7.5 | -15.56 | -25.45 | -10.66 |
| Return on Assets (ROA) | 10.79 | 4.43 | 3.51 | -1.37 | 1.68 |
| Operating Margin | 11.45 | 5.04 | 4.44 | -2.05 | 3.53 |
| Net Margin | 6.87 | -4.32 | -7.78 | -19.52 | -13.73 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days score well, indicating efficient inventory and accounts receivable management, the turnover ratios for fixed assets, inventory, receivables, and capital are low. This suggests potential inefficiencies in asset utilization and revenue generation. This assessment is based on a weighted average calculation, emphasizing recent performance.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 4.52 | 2.24 | 1.75 | 1.58 | 1.41 |
| Inventory Turnover Ratio | 4.21 | 4.06 | 4.02 | 4.26 | 4.03 |
| Receivables Turnover Ratio | 4.03 | 4.34 | 6.55 | 8.72 | 9.46 |
| Days Sales in Inventory Ratio | 86.7 | 89.9 | 90.8 | 85.68 | 90.57 |
| Receivable Days | 90.57 | 84.1 | 55.73 | 41.86 | 38.58 |
| Capital Turnover Ratio | 1.26 | 1.11 | 1.05 | 0.8 | 0.57 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are low, with both interest and equity dividend coverage scoring poorly. This suggests potential difficulties in meeting interest and dividend obligations. This assessment is based on a weighted average calculation, emphasizing recent performance.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | N/A | -0.67 | -2.2 | -4.27 | -3.71 |
| Equity Dividend Coverage Ratio | 2.38 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, characterized by a high equity ratio and no debt. This indicates a robust financial structure with minimal reliance on external financing. The company's financial stability provides a solid foundation for future growth. This assessment is based on a weighted average calculation, emphasizing recent performance.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.14 | 0.36 | 0.47 | 0.38 | 0.26 |
| Debt to Equity Ratio | 0.16 | 0.56 | 0.89 | 0.61 | 0.35 |
| Equity Ratio | 0.86 | 0.64 | 0.53 | 0.62 | 0.74 |
| Debt To Asset Ratio | 0.11 | 0.28 | 0.36 | 0.32 | 0.22 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, with all liquidity ratios (Current, Quick, Cash, and Operating Cash Flow) scoring poorly. This suggests potential difficulties in meeting short-term obligations. On the positive side, the company has the opportunity to improve its working capital management to enhance its financial flexibility. This assessment is based on a weighted average calculation, emphasizing recent performance.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.58 | 2 | 2.51 | 2.56 |
| Quick Ratio | 1.37 | 1.3 | 1.07 | 1.13 | 1.53 |
| Cash Ratio | 0.06 | 0.03 | 0.02 | 0.05 | 0.51 |
| Operating Cash Flow Ratio | 0.37 | -0.06 | -0.1 | -0.65 | -0.44 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | FDC Ltd | 7.64 | 22.52 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.30 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 10 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Shilpa Medicare Ltd | 5.94 | 44.32 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 16 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 17 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 20 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
The management effectiveness of Zota Health Care Ltd appears weak due to deteriorating profitability and increasing debt. While sales growth has been strong, it hasn't translated into improved profitability, indicating operational inefficiencies. A notable decrease in promoter holding further raises concerns. The financial performance and strategic indicators suggest a need for significant improvements in management's approach.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth | 62% (TTM) | Strong Sales Growth |
| CONS | Profit Growth | -293% (TTM) | Declining Profit Growth |
| Operating Profit Margin | -2% (Mar 2025) | Declining Operational Efficiency | |
| Promoter Holding | 58.11% (Apr 2025) | Decreasing Promoter Confidence |
Financial Performance & Growth
Zota Health Care Ltd demonstrates concerning trends in financial performance and growth. While sales growth has been robust, the company struggles with profitability. The compounded profit growth is significantly negative. Declining OPM and net profit margins indicate operational inefficiencies affecting the bottom line.
| Metric | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---| |Compounded Sales Growth (%) | 31% | 31% | 31% | 62% | |Compounded Profit Growth (%) | - | - | - | -293% |
Zota Health Care has experienced fluctuating sales and profit figures. Sales have generally increased, but profitability has declined, particularly in recent quarters. This inconsistency raises concerns about the sustainability of the company's earnings.The decline in profitability despite sales growth indicates potential issues with cost management or pricing strategies.
Capital Efficiency & Returns
Zota Health Care Ltd exhibits poor capital efficiency and returns. The current and historical ROCE values are negative, indicating that the company is not effectively utilizing its capital. ROE is also negative, suggesting that shareholder funds are not generating satisfactory returns.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | |---|---|---|---|---| | ROCE (%) | -2% | 15% | -2% | -7% | -17% | | ROE (%) | - | - | - | - | -36% |
The Cash Conversion Cycle is notably high, reflecting inefficiencies in working capital management. This indicates that the company is taking longer to convert its investments in inventory and receivables into cash, potentially straining its liquidity and increasing its financing needs.
Financial Health & Prudence
Zota Health Care Ltd's financial health and prudence are weak. The company's borrowings have increased significantly over the years, leading to a higher debt/equity ratio. Interest coverage is declining, indicating difficulties in covering interest obligations comfortably.
| Metric | 2022 | 2023 | 2024 | 2025 | |---|---|---|---| | Borrowings (₹ Cr) | 15 | 45 | 95 | 140 | | Interest (₹ Cr) | 0 | 3 | 5 | 11 |
The increasing debt poses a significant risk, potentially leading to financial distress if profitability does not improve.
Shareholding & Ownership Structure
Zota Health Care Ltd shows an average shareholding and ownership structure. The promoter holding has decreased over the recent quarters, indicating a potential lack of confidence or strategic shift. Institutional holding, while present, is relatively low, suggesting limited interest from institutional investors.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Apr 2025 | |---|---|---|---| | Promoter Holding (%) | 68.12% | 66.15% | 59.72% | 58.11% |
This decline in promoter holding could signal a shift in the company's strategic direction or a decrease in confidence among the promoters. The relatively low institutional holding indicates that the company may not be as attractive to institutional investors, potentially affecting its stock liquidity and valuation.
The risk assessment for Zota Health Care Ltd is red, indicating a high level of concern. The company's segment performance volatility, and increasing regulatory compliance costs contribute to this elevated risk profile. The negative trends in profitability, coupled with increasing debt, further amplify the risks.
Segment performance volatility
Zota Health Care Ltd shows significant volatility in its quarterly results. The operating profit margin (OPM) fluctuates from positive to negative values, indicating instability in operational efficiency.
| Quarter | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | |---|---|---|---|---| | OPM (%) | -3% | -2% | -1% | -8% | 3% |
This variability indicates that Zota Health Care must proactively manage its diverse segments to ensure consistent overall financial health.
Foreign exchange or interest rate exposure
Given the increasing borrowings and interest expenses, Zota Health Care Ltd is likely exposed to interest rate risk. Fluctuations in interest rates could impact the company's profitability.
Regulatory compliance cost trends
The increase in 'Expenses' indicate potential regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 101302.71Bearish
- SMA 201274.01Bullish
- SMA 501245.12Bullish
- EMA 101298.49Bearish
- EMA 201281.80Bullish
- EMA 501254.21Bullish
- DEMA 101313.85Bearish
- DEMA 201309.14Bearish
- DEMA 501284.49Bullish
- TEMA 101310.25Bearish
- TEMA 201319.02Bearish
- TEMA 501299.00Bearish
- MACD20.89Bullish
- ADX38.38Strong Trend
- IndicatorValueSignal
- RSI55.42Neutral
- CCI56.33Neutral
- ROC 91.86Bullish
- ROC 145.47Bullish
- ROC 256.51Bullish
- Stoch K57.79Neutral
- Stoch D61.54Neutral
- IndicatorValueSignal
- BB Upper1352.84Neutral
- BB Middle1274.01Neutral
- BB Lower1195.17Neutral
- ATR21.40High Volatility
- IndicatorValueSignal
- MFI81.46Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 101279.33Bullish
- SMA 201255.20Bullish
- SMA 501234.79Bullish
- EMA 101283.16Bullish
- EMA 201263.10Bullish
- EMA 501236.31Bullish
- DEMA 101307.56Bearish
- DEMA 201291.30Bullish
- DEMA 501260.94Bullish
- TEMA 101314.28Bearish
- TEMA 201304.13Bearish
- TEMA 501283.50Bullish
- MACD22.81Bullish
- ADX41.47Strong Trend
- IndicatorValueSignal
- RSI58.78Neutral
- CCI94.64Neutral
- ROC 95.81Bullish
- ROC 146.86Bullish
- ROC 258.06Bullish
- Stoch K61.56Neutral
- Stoch D67.95Neutral
- IndicatorValueSignal
- BB Upper1328.36Neutral
- BB Middle1255.21Neutral
- BB Lower1182.05Neutral
- ATR27.45Low Volatility
- IndicatorValueSignal
- MFI80.47Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 101253.36Bullish
- SMA 201232.80Bullish
- SMA 501201.80Bullish
- EMA 101259.20Bullish
- EMA 201239.25Bullish
- EMA 501221.15Bullish
- DEMA 101284.41Bullish
- DEMA 201265.92Bullish
- DEMA 501229.64Bullish
- TEMA 101294.49Bearish
- TEMA 201283.27Bullish
- TEMA 50N/AN/A
- MACD21.63Bullish
- ADX37.54Strong Trend
- IndicatorValueSignal
- RSI61.53Neutral
- CCI161.91Overbought
- ROC 91.68Bullish
- ROC 146.60Bullish
- ROC 259.25Bullish
- Stoch K67.10Neutral
- Stoch D67.92Neutral
- IndicatorValueSignal
- BB Upper1297.92Neutral
- BB Middle1232.80Neutral
- BB Lower1167.69Neutral
- ATR37.66Low Volatility
- IndicatorValueSignal
- MFI83.31Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101232.16Bullish
- SMA 201199.76Bullish
- SMA 501244.35Bullish
- SMA 1001238.24Bullish
- SMA 2001370.60Bearish
- EMA 101240.34Bullish
- EMA 201224.90Bullish
- EMA 501227.83Bullish
- EMA 1001257.35Bullish
- EMA 2001258.11Bullish
- DEMA 101267.48Bullish
- DEMA 201236.21Bullish
- DEMA 501204.51Bullish
- DEMA 1001209.38Bullish
- DEMA 2001331.97Bearish
- TEMA 101284.49Bullish
- TEMA 201255.88Bullish
- TEMA 501224.18Bullish
- TEMA 1001162.42Bullish
- TEMA 2001230.05Bullish
- MACD12.27Bullish
- ADX28.66Strong Trend
- IndicatorValueSignal
- RSI61.84Neutral
- CCI197.77Overbought
- ROC 1416.21Bullish
- ROC 258.69Bullish
- Stoch K73.51Neutral
- Stoch D67.83Neutral
- IndicatorValueSignal
- BB Upper1302.79Overbought
- BB Middle1199.76Neutral
- BB Lower1096.72Neutral
- ATR55.75High Volatility
- IndicatorValueSignal
- MFI79.92Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 201232.48Bearish
- SMA 501346.43Bearish
- EMA 201256.12Bearish
- EMA 501239.79Bearish
- DEMA 201210.06Bullish
- DEMA 501364.39Bearish
- TEMA 201173.80Bullish
- TEMA 501283.46Bearish
- MACD-33.31Bullish
- ADX20.69Weak Trend
- IndicatorValueSignal
- RSI48.54Neutral
- CCI-58.94Neutral
- ROC 142.25Bullish
- ROC 25-20.92Bearish
- Stoch K52.31Neutral
- Stoch D45.76Neutral
- IndicatorValueSignal
- BB Upper1413.51Neutral
- BB Middle1232.48Neutral
- BB Lower1051.46Neutral
- ATR114.73Low Volatility
- IndicatorValueSignal
- MFI49.60Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 61258.25Bearish
- SMA 121285.91Bearish
- SMA 241013.05Bullish
- EMA 61227.24Bearish
- EMA 121199.64Bearish
- EMA 241043.63Bullish
- DEMA 61197.35Bearish
- DEMA 121321.17Bearish
- DEMA 241333.93Bearish
- TEMA 61133.82Bearish
- TEMA 121254.41Bearish
- TEMA 241394.78Bearish
- MACD288.74Bullish
- ADX59.25Strong Trend
- IndicatorValueSignal
- RSI59.10Neutral
- CCI99.46Neutral
- ROC 25133.59Bullish
- ROC 50278.09Bullish
- Stoch K74.67Neutral
- Stoch D78.40Neutral
- IndicatorValueSignal
- BB Upper1672.06Neutral
- BB Middle1093.19Neutral
- BB Lower514.33Neutral
- ATR207.95High Volatility
- IndicatorValueSignal
- MFI71.96Neutral